Top Markets
Coin of the day
Organogenesis Holdings Inc. Organogenesis Holdings Inc.

Organogenesis Holdings Inc.

ORGO
주식 순위 #17996
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that... Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
주가
$1.69
마지막 동기화: 2026-09-02
시가총액
$216.83M
변동 (1일)
3.38%
변동 (1년)
-66.03%
국가
US
거래 Organogenesis Holdings Inc. (ORGO)

카테고리

Organogenesis Holdings Inc. (ORGO)의 주식 분할 이력
Organogenesis Holdings Inc. 주식 (심볼: ORGO)은 총 0회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Sep 03, 2026에 발생했습니다.
Sep 03, 2026 이전에 매수한 ORGO 주식 1주는 현재 0주의 ORGO 주식에 해당합니다.
주식 분할 목록
연도 주식 분할 배수 누적 배수
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 주식 분할